ProQR reports Q3 2026 results, fully enrolls AX-0811 cohorts 1 and 2
ProQR said it expects initial AX-0811 target engagement data in early January 2027 and ended the quarter with €103 million in cash, extending runway into mid-2028.
SEC filing
3 stories
ProQR said it expects initial AX-0811 target engagement data in early January 2027 and ended the quarter with €103 million in cash, extending runway into mid-2028.
SEC filing
The moves are meant to expand AI use across ProQR's Axiomer RNA editing programs, with an early readout for lead AI-discovered candidate AX-0811 expected in January 2027.
SEC filing
The clinical-stage RNA editing company also set a September 30, 2026 investor event to discuss NTCP modulation in biliary atresia.
SEC filing